Conivaptan (YM 087 brand name Vaprisol) is a non-peptide inhibitor of antidiuretic hormone (vasopressin receptor antagonist). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) and there is some evidence it may be effective in heart failure. It is marketed by Astellas Pharma Inc.Conivaptan inhibits two of the three subtypes of the vasopressin receptor (V1a and V2).
This page contains content from the copyrighted Wikipedia article "Conivaptan"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
